McKinley: A double-blind study, in which neither the patient nor the primary researcher knows whether the patient is being given the drug being tested or a placebo, is the most effective procedure for testing the efficacy of a drug. ███ ██ ████ ███ ██ ████ ██ ███████ ████ █ █████ ██ ████ ███ █████ █████ ███ ████ ████ ████ ███████ ███████ ██ ███ █████████ ███████ █████ ████ ████ ██ █████ ██ ███████ ███ ████████ ███ ███████ ███ ████ ██ █ ████████
██████ ███ ██████ ████ ████ ██████████ ██ ████ ██████ ███ ███ ███ ████████ ███ ████ ████ ███ ███████ ██ ███ █████ ████ ███
McKinley argues that, because the new drug will produce a visible effect in those who take it, it won't be possible to use a double-blind study to determine the drug's efficacy.
Engle counters by saying that McKinley assumes what result the study will yield. However, McKinley doesn't make any claim about what the outcome will be—only that the test can't be conducted blindly because the drug produces some visible effects.
Engle appears to think that when McKinley refers to the “various effects” of the drug, he’s referring to the drug’s intended effects (efficacy), when in fact, McKinley is merely referring to its visible ones.
Engle's statement indicates that he ██ ████ ██████ ████████████ ██████████ ███████ ██ ██
presuming that a ████████████ █████ ██ ███ ████ █████████ ███ ██ ████ ███ █████
denying that the ████ ████ ██ █████████
presuming that the ███████ ████ ███████ ██ ███████ ████████ ██ ███ █████████ ██████
referring to the ██████ ███████████ ███████ ██████ ████ ██ ███ █████ ████ ███████
based on a █████████ █████ ████ █ ████ ██ ███████████